<DOC>
	<DOCNO>NCT02384850</DOCNO>
	<brief_summary>This trial evaluate combination treatment establish chemotherapy regimen mFOLFOX6 Selinexor , oral Selective Inhibitor Of Nuclear Export , patient metastatic Colorectal Cancer . The purpose determine maximum tolerate dose ( MTD ) selinexor combination mFOLFOX6 .</brief_summary>
	<brief_title>Phase 1 Trial To Evaluate mFOLFOX6 With Selinexor In Patients With Metastatic Colorectal Cancer</brief_title>
	<detailed_description />
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<mesh_term>Oxaliplatin</mesh_term>
	<mesh_term>Leucovorin</mesh_term>
	<mesh_term>Levoleucovorin</mesh_term>
	<mesh_term>Folic Acid</mesh_term>
	<criteria>1 . Patients histologically confirm diagnosis colorectal cancer present unresectable stage IV ( UICC ) disease ( primary tumor may present ) 2 . Patients feasible treatment FOLFOX ( prior adjuvant palliative treatment allow ) 3 . ECOG Performance status ≤ 1 4 . Life expectancy &gt; 3 month 5 . Age ≥18 year 6 . Haematologic function follow ( 5 % deviation allow ) : ANC ≥ 1.5 x 109/L platelet ≥ 100 x109/L hemoglobin ≥ 9 g/dl 5.59 mmol/l 7 . Adequate liver function follow ( 10 % deviation allow ) serum alanine transaminase ( ALT ) ≤ 2.5 x ULN ( case liver metastases &lt; 5 x ULN ) total bilirubin ≤ 1.5 x ULN ( patient Gilbert 's syndrome total bilirubin ≤2.5 x ULN ) 8 . Adequate renal function follow ( 10 % deviation allow ) · creatinine ≤ 1.5 x ULN 9 . Signed write informed consent 10 . Women childbearing potential must negative pregnancy test adequately control appropriate therapy would compromise patient 's ability tolerate therapy ; 2 . Treatment systemic anticancer therapy ≤ 3 week prior cycle 1 day 1 3 . Uncontrolled active infection ( Hepatitis B C infection NOT exclusion criterion ) and/or know HIV infection ; 4 . Renal failure require haemodialysis peritoneal dialysis ; 5 . Patients pregnant breastfeeding ; 6 . Patients significantly diseased obstruct gastrointestinal tract , malabsorption , uncontrolled vomit diarrhea result inability swallow oral medication ; 7 . Presence symptomatic CNS metastasis 8 . Unresolved toxicity previous anticancer therapy incomplete recovery surgery , particular oxaliplatininduced peripheral neuropathy &gt; grade 1 . 9 . Any follow within 12 month prior study drug administration : myocardial infarction , severe/unstable angina , coronary/peripheral artery bypass graft , symptomatic congestive heart failure , cerebrovascular accident transient ischemic attack , pulmonary embolism , deep vein thrombosis , thromboembolic event .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>metastatic</keyword>
</DOC>